Fudan Team Presents Ribociclib Phase II Bridging Study Results at ESMO Asia
A Fudan University Shanghai Cancer Center team led by Shao Zhimin made an oral presentation...
Hansoh’s EGFR Inhibitor Ameile Filed for EMA Review by Partner EQRx
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a market filing for its...
Sinocelltech’s SCTV01C Vaccine Included in China’s Emergency Use Program
China-based Sinocelltech Group Ltd (SHA: 688520) announced the inclusion of its recombinant novel coronavirus alpha+beta...
Lynk Pharmaceuticals Doses First Patient in Phase II Study for LNK01003
China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd announced first patient dosing in a Phase II clinical...
Lavamed Secures USD 40M in Angel and Series A Financing Rounds
Lavamed, a high-end neurointervention device maker based in Suzhou, has successively closed angel and Series...
Innovent Biologics Doses First Volunteer in Orismilast Phase I Study
China-based Innovent Biologics Inc., (HKG: 1801) and Denmark-based partner Union Therapeutics A/S revealed that a...
Daiichi Sankyo Doses First Patient in Global Phase III TROPION-Lung08 Study
Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced the first patient dosed in the global multi-center...
Tsingke Biotech Secures RMB 400M Series B Financing for Expansion
Beijing Tsingke Biotech Co., Ltd. a gene synthesis company based in Beijing, reportedly raised RMB...
China Medical System Licenses Opzelura from Incyte for Greater China and Southeast Asia
China Medical System Holdings (CMS; HKG: 0867) announced the establishment of a licensing agreement with...
SAFE Raises RMB 500M in Series D Financing to Expand CRO Services
Serve Accurate Faithful Evaluation (SAFE), a contract research organization (CRO) co-founded by the Chinese Academy...
Peijia Medical Enrolls First Patient in GeminiOne TEER System Study
China’s Peijia Medical Ltd (HKG: 9996) announced first patient enrollment in a multi-center clinical study...
NMPA Approves Henlius’ HLX04 Biosimilar for Lung and Colorectal Cancer
The National Medical Products Administration (NMPA) website indicates that China-based Shanghai Henlius Biotech’s (HKG: 2696)...
Yifan Pharma Transfers F-627 Distribution Rights in Germany to Apogepha
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced the transfer of exclusive distribution rights in...
Pyxis Oncology Receives FDA Approval for Biosion’s PYX-106 Clinical Trials
China-based Biosion, Inc’s US partner Pyxis Oncology, Inc. (NASDAQ: PYXS) announced receiving clinical trial approval...
Eli Lilly Ends License for Innovent’s Tyvyt Outside China
Eli Lilly & Co’s (NYSE: LLY) Q3 2022 SEC filing released last month revealed that...
Novartis Partners with Sinopharm for Commercial Promotion of Gleevec and Exjade in China
Swiss giant Novartis (NYSE: NVS) entered into a promotion agreement with China-based Sinopharm Group Co.,...
Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine
China-based Luye Pharma Group (HKG: 2186), Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262), and Beijing...
Pediatrix Therapeutics Licenses Tris Pharma’s ADHD Portfolio for Greater China
China-based Pediatrix Therapeutics announced a licensing agreement with US firm Tris Pharma, Inc., obtaining exclusive...
Hainan’s New Regulations on Medical Devices in Boao Lecheng to Take Effect in 2023
The “Regulations on the Administration of Medical Devices in Boao Lecheng International Medical Tourism Pilot...
Kintor’s KX-826 Reaches Primary Endpoint in Phase II Study for Female AGA
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced that the Phase II clinical study for its...